Диссертация (1140920), страница 20
Текст из файла (страница 20)
European urology2014, 65(1):7-16.Rees T, Raison N, Sheikh MI, Jaffry Z, Madaan S, Challacombe B, AhmedK, Dasgupta P: Is extended pelvic lymph node dissection for prostatecancer the only recommended option? A systematic over-view of theliterature. Turkish journal of urology 2016, 42(4):240-246.Schroder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L,Collette L: Early versus delayed endocrine treatment of T2-T3 pN1-3 M0prostate cancer without local treatment of the primary tumour: finalresults of European Organisation for the Research and Treatment ofCancer protocol 30846 after 13 years of follow-up (a randomisedcontrolled trial). European urology 2009, 55(1):14-22.Engel J, Bastian PJ, Baur H, Beer V, Chaussy C, Gschwend JE, Oberneder R,Rothenberger KH, Stief CG, Holzel D: Survival benefit of radicalprostatectomy in lymph node-positive patients with prostate cancer.European urology 2010, 57(5):754-761.Нюшко К, Крашенинников А, Сергиенко С, Алексеев Б, Калпинский А,ВоробьевН,СафроноваЕ,КапринА:Спасительнаялимфаденэктомия у больных раком предстательной железы.Research'n Practical Medicine Journal 2016(Спецвыпуск):1.Алексеев БЯ, Нюшко КМ, Воробьев НВ, Калпинский АС, ГоловащенкоМП, Франк ГА, Андреева ЮЮ: Частота и локализация метастазов влимфатическихузлахпривыполнениирадикальнойпростатэктомии и расширенной тазовой лимфаденэктомии убольных раком предстательной железы.
Онкоурология 2012:77-82.Алексеев Б, Нюшко К: Радикальная простатэктомия с расширеннойтазовой лимфаденэктомией и адъювантная гормональная терапияу больных лимфогенно-диссеминированным раком предстательнойжелезы. Онкоурология 2011, 7:118-121.Сергиенко СА, Крашенинников АА, Нюшко КМ, Алексеев БЯ,Сафронова ЕЮ, Калпинский АС, Воробьев НВ, Каприн АД: Факторыпрогнозабиохимическогорецидиваубольныхракомпредстательной железы с лимфогенными метастазами послехирургического лечения. I Национальный конгресс "онкологиярепродуктивных органов: от профилактики и раннего выявления кэффективному лечению"; 2016.Tilki D, Mandel P, Seeliger F, Kretschmer A, Karl A, Ergun S, Seitz M, StiefCG: Salvage lymph node dissection for nodal recurrence of prostatecancer after radical prostatectomy. The Journal of urology 2015,193(2):484-490.Ochoa C, Ramirez A, Varela R, Godoy F, Vargas R, Forero J, Rojas A, RoaC, Cespedes C, Ramos J et al: Metastasectomy of Abdominal Wall Lesionsdue to Prostate Cancer Detected Through PET/CT Gallium 68-PMSA:First Case Report.
Urology case reports 2017, 12:42-44.11687.88.89.90.91.92.93.94.95.96.97.Krupski TL, Saigal CS, Litwin MS: Variation in continence and potencyby definition. The Journal of urology 2003, 170(4 Pt 1):1291-1294.Khoder WY, Trottmann M, Stuber A, Stief CG, Becker AJ: Earlyincontinence after radical prostatectomy: a community basedretrospective analysis in 911 men and implications for preoperativecounseling. Urologic oncology 2013, 31(7):1006-1011.Geraerts I, Van Poppel H, Devoogdt N, Van Cleynenbreugel B, Joniau S, VanKampen M: Prospective evaluation of urinary incontinence, voidingsymptoms and quality of life after open and robot-assisted radicalprostatectomy.
BJU international 2013, 112(7):936-943.Vasdev N, Agarwal S, Rai BP, Soosainathan A, Shaw G, Chang S, Prasad V,Mohan SG, Adshead JM: Intraoperative Frozen Section of the ProstateReduces the Risk of Positive Margin Whilst Ensuring Nerve Sparing inPatients with Intermediate and High-Risk Prostate Cancer UndergoingRobotic Radical Prostatectomy: First Reported UK Series. Currenturology 2016, 9(2):93-103.Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, Litwin MS:Predicting quality of life after radical prostatectomy: results fromCaPSURE.
The Journal of urology 2004, 171(2 Pt 1):703-707; discussion707-708.Joniau S, Van den Bergh L, Lerut E, Deroose CM, Haustermans K, Oyen R,Budiharto T, Ameye F, Bogaerts K, Van Poppel H: Mapping of pelvic lymphnode metastases in prostate cancer. European urology 2013, 63(3):450458.Jeschke S, Lusuardi L, Myatt A, Hruby S, Pirich C, Janetschek G:Visualisation of the lymph node pathway in real time by laparoscopicradioisotope- and fluorescence-guided sentinel lymph node dissection inprostate cancer staging. Urology 2012, 80(5):1080-1086.Аляев ЮГ, Безруков ЕА, Сирота ЕС, Морозов АО: Флуоресцентнаявизуализация с Индоцианином Зелёным в урологии. Урология 2016,1:106-111.Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R:Radioisotope guided pelvic lymph node dissection for prostate cancer.The Journal of urology 2001, 166(5):1715-1719.Русаков ИГ, Алексеев БЯ, Нюшко КМ, Франк ГА, Белова ЕА, БеспаловПД, Воробьев НВ, Поляков ВА: Радиоизотопная лимфосцинтиграфиякак метод уточняющей диагностики метастатического поражениялимфатическихузловубольныхлокализованнымиместнораспространенным раком предстательной железы.
Вопросыонкологии 2006, 52:686-690.Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, LangstegerW, Janetschek G: Detection of pelvic lymph node metastases in patientswith clinically localized prostate cancer: comparison of[18F]fluorocholine positron emission tomography-computerized11798.99.100.101.102.103.104.105.106.107.108.tomography and laparoscopic radioisotope guided sentinel lymph nodedissection. The Journal of urology 2006, 176(5):2014-2018; discussion 20182019.Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI,Partin AW: Updated nomogram to predict pathologic stage of prostatecancer given prostate-specific antigen level, clinical stage, and biopsyGleason score (Partin tables) based on cases from 2000 to 2005.
Urology2007, 69(6):1095-1101.Winter A, Kneib T, Rohde M, Henke RP, Wawroschek F: First NomogramPredicting the Probability of Lymph Node Involvement in ProstateCancer Patients Undergoing Radioisotope Guided Sentinel Lymph NodeDissection. Urologia internationalis 2015, 95(4):422-428.Holl G, Dorn R, Wengenmair H, Weckermann D, Sciuk J: Validation ofsentinel lymph node dissection in prostate cancer: experience in morethan 2,000 patients. European journal of nuclear medicine and molecularimaging 2009, 36(9):1377-1382.Rosenthal EL, Warram JM, Bland KI, Zinn KR: The status of contemporaryimage-guided modalities in oncologic surgery.
Annals of surgery 2015,261(1):46-55.Polom W, Markuszewski M, Rho YS, Matuszewski M: Use of invisible nearinfrared light fluorescence with indocyanine green and methylene blue inurology. Part 2. Central European journal of urology 2014, 67(3):310-313.Reuthebuch O, Haussler A, Genoni M, Tavakoli R, Odavic D, Kadner A,Turina M: Novadaq SPY: intraoperative quality assessment in off-pumpcoronary artery bypass grafting.
Chest 2004, 125(2):418-424.Desmettre T, Devoisselle JM, Mordon S: Fluorescence properties andmetabolic features of indocyanine green (ICG) as related to angiography.Survey of ophthalmology 2000, 45(1):15-27.Nakajima T, Mitsunaga M, Bander NH, Heston WD, Choyke PL, KobayashiH: Targeted, activatable, in vivo fluorescence imaging of prostate-specificmembrane antigen (PSMA) positive tumors using the quenchedhumanized J591 antibody-indocyanine green (ICG) conjugate.Bioconjugate chemistry 2011, 22(8):1700-1705.Manny TB, Patel M, Hemal AK: Fluorescence-enhanced robotic radicalprostatectomy using real-time lymphangiography and tissue markingwith percutaneous injection of unconjugated indocyanine green: theinitial clinical experience in 50 patients.
European urology 2014,65(6):1162-1168.Hruby S, Englberger C, Lusuardi L, Schatz T, Kunit T, Abdel-Aal AM, HagerM, Janetschek G: Fluorescence Guided Targeted Pelvic Lymph NodeDissection for Intermediate and High Risk Prostate Cancer. The Journalof urology 2015, 194(2):357-363.Young HH: Use of radium in cancer of the prostate and bladder. Jama1917, 68:1174-1177.118109.
Holm H: Transperineal iodine-125 seed implantation in prostate cancerguided by transrectal ultrasonography. Jourmal of Urology 1983, 130:283286.110. Del Regato JA: Radiotherapy in the conservative treatment of operableand locally inoperable carcinoma of the prostate. Radiology 1987, 88:761766.111. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, LundJA, Tasdemir I, Hoyer M, Wiklund F et al: Endocrine treatment, with orwithout radiotherapy, in locally advanced prostate cancer (SPCG7/SFUO-3): an open randomised phase III trial.
Lancet 2009,373(9660):301-308.112. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD,Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM et al: Ten-yearfollow-up of radiation therapy oncology group protocol 92-02: a phase IIItrial of the duration of elective androgen deprivation in locally advancedprostate cancer.
Journal of clinical oncology : official journal of theAmerican Society of Clinical Oncology 2008, 26(15):2497-2504.113. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, StormeG, Bernier J, Kuten A, Sternberg C et al: Long-term results with immediateandrogen suppression and external irradiation in patients with locallyadvanced prostate cancer (an EORTC study): a phase III randomisedtrial. Lancet 2002, 360(9327):103-106.114.
Ishiyama H, Satoh T, Kitano M, Tabata K, Komori S, Ikeda M, Soda I,Kurosaka S, Sekiguchi A, Kimura M et al: High-dose-rate brachytherapyand hypofractionated external beam radiotherapy combined with longterm hormonal therapy for high-risk and very high-risk prostate cancer:outcomes after 5-year follow-up. Journal of radiation research 2014,55(3):509-517.115. Дзрьялова СЛ, Алексеев БЯ, Гришина ЮА: Отдаленные результатылучевой терапии локализованного и местно-распространенногорака предстательной железы. Российский онкологический журнал2008, 2:22-28.116. Kalbasi A, Li J, Berman A, Swisher-McClure S, Smaldone M, Uzzo RG,Small DS, Mitra N, Bekelman JE: Dose-Escalated Irradiation and OverallSurvival in Men With Nonmetastatic Prostate Cancer.
JAMA oncology2015, 1(7):897-906.117. Nomiya T, Tsuji H, Toyama S, Maruyama K, Nemoto K, Tsujii H, KamadaT: Management of high-risk prostate cancer: radiation therapy andhormonal therapy. Cancer treatment reviews 2013, 39(8):872-878.118. Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, AirdEG, Bottomley D, Huddart RA, Jose CC et al: Escalated-dose versuscontrol-dose conformal radiotherapy for prostate cancer: long-termresults from the MRC RT01 randomised controlled trial.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
